 |
Five Prime Therapeutics - Protein Medicines
Interview with Rusty Williams, MD, PhD, Executive Chairman and Founder; and Julia P. Gregory, President and CEO
11:23 | February 17, 2010
Essinova host BeiBei Song visits Five Prime Therapeutics, Inc. and speaks with its senior executives about the company's discovery platform, pipeline status, and strategic initiatives for 2010.
Five Prime Therapeutics, Inc. is a clinical-stage biotech company discovering innovative protein and antibody therapeutics using its unique discovery engine. The company's pipeline of biologics includes FP-1039, an oncology product in a phase 1 trial, and multiple preclinical and research programs in oncology, metabolic disease and immunology. The company uses its discovery platform to comprehensively screen secreted proteins and receptors using novel cell-based and in vivo screening systems. |
 |
Chemokine Therapeutics from ChemoCentryx
Interview with CEO, Thomas J. Schall, PhD, at JP Morgan Healthcare Conference
06:32 | February 2, 2010
Essinova host BeiBei Song interviews Dr. Thomas J. Schall, Founder and CEO of ChemoCentryx Inc., during the 2010 JP Morgan Healthcare Conference in San Francisco.
ChemoCentryx is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered small molecule therapeutics that target the chemokine and chemo-attractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer.
Earlier in January, GlaxoSmithKline (GSK) exercised its option to obtain an exclusive license for further development and worldwide commercialization of ChemoCentryx' lead product candidate, Traficet-EN™ (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease. |
 |
China’s life science industry is moving quickly from services to innovation. In the 2010 ChinaBio Executive Workshop "Leveraging China to Build a Global Biotech", hosted at Morrison & Foerster's San Francisco office during the 28th JP Morgan Healthcare Conference, Greg Scott presents the latest update on China's government programs, novel technology development, investment, M&A and partnering deals, and other data from ChinaBio’s research team.
Watch this video series for not only hot-off-the-press facts and figures, but also stories and anecdotes witnessed or experienced by a pioneering firm, on the frontline of bio-business in the world's fastest growing but complex country. |
 |
China’s life science industry is moving quickly from services to innovation. In the 2010 ChinaBio Executive Workshop "Leveraging China to Build a Global Biotech", hosted at Morrison & Foerster's San Francisco office during the 28th JP Morgan Healthcare Conference, Greg Scott presents the latest update on China's government programs, novel technology development, investment, M&A and partnering deals, and other data from ChinaBio’s research team.
Watch this video series for not only hot-off-the-press facts and figures, but also stories and anecdotes witnessed or experienced by a pioneering firm, on the frontline of bio-business in the world's fastest growing but complex country. |
 |
China’s life science industry is moving quickly from services to innovation. In the 2010 ChinaBio Executive Workshop "Leveraging China to Build a Global Biotech", hosted at Morrison & Foerster's San Francisco office during the 28th JP Morgan Healthcare Conference, Greg Scott presents the latest update on China's government programs, novel technology development, investment, M&A and partnering deals, and other data from ChinaBio’s research team.
Watch this video series for not only hot-off-the-press facts and figures, but also stories and anecdotes witnessed or experienced by a pioneering firm, on the frontline of bio-business in the world's fastest growing but complex country. |
 |
ChinaBio Accelerator
Helping US life science companies leverage China's resources
05:42 | January 27, 2010
At the 2010 ChinaBio Executive Workshop "Leveraging China to Build a Global Biotech", hosted at Morrison & Foerster's San Francisco office during the 28th JP Morgan Healthcare Conference, Greg Scott announces ChinaBio Accelerator, the latest addition to ChinaBio's impressive service portfolio. |
 |
Developing RNAi Therapeutics (Part I)
An interview with Patrick Lu, Founder and CEO of Sirnaomics, Inc.
09:00 | September 14, 2009
Essinova host BeiBei Song interviewed Patrick Lu, Ph.D., Founder and CEO of Sirnaomics, Inc, about the science and business of developing RNAi therapeutics during the IBC Oligonucleotide Therapeutics conference in Boston.
In this segment, Dr. Lu comments on the potential of RNAi therapeutics as the "Next Big Thing" in drug discovery and development, the scientific challenges of realizing such potential, and the latest technological development in the field as evidenced in the meeting. |
 |
Developing RNAi Therapeutics (Part II)
An interview with Patrick Lu, Founder and CEO of Sirnaomics, Inc.
09:24 | September 14, 2009
Essinova host BeiBei Song interviewed Patrick Lu, Ph.D., Founder and CEO of Sirnaomics, Inc, about the science and business of developing RNAi therapeutics during the IBC Oligonucleotide Therapeutics conference in Boston.
In this segment, Dr. Lu responds to questions about potential risks inherent in RNAi therapeutics in terms of toxicity and specificity, and explains ways to mitigate those risks. He also provides his take on where "breakthrough" may emerge and discusses Sirnaomics clinical strategy in developing siRNA drugs. |
 |
Developing RNAi Therapeutics (Part III)
An interview with Patrick Lu, Founder and CEO of Sirnaomics, Inc.
05:48 | Sepbember 14, 2009
Essinova host BeiBei Song interviewed Patrick Lu, Ph.D., Founder and CEO of Sirnaomics, Inc, about the science and business of developing RNAi therapeutics during the IBC Oligonucleotide Therapeutics conference in Boston.
In this last segment, Dr. Lu addresses IP issues specific to RNAi therapeutic development and Sirnaomics' IP strategy. He also shares his experience operating in China, commenting on various advantages China offers to developing cutting edge technologies such as siRNA, from efficiency and talent to financial resources.
|
 |
The Evolving Treatment Paradigm in Myeloma
An Interview with Kenneth C. Anderson, M.D., Dana Farber Cancer Institute / Harvard Medical School
17:47 | September 5, 2009
In this interview by Essinova host BeiBei Song on August 6, 2009 during the IBC Cancer Drug Development Conference in Boston, Dr. Kenneth C. Anderson discusses the effectiveness of combination targeted therapies in the treatment of cancer, as exemplified by multiple myeloma. Phase I-II trials combining two or more novel agents targeting the bone marrow microenvironment, such as Lenalidomide and Bortezomib, have shown significant higher response rates, lower drug resistance and fewer side effects in myeloma patients, according to Dr. Anderson. He also comments on trends shown in the meeting and explains the two ways "combinations" can occur. More...
|
 |
The Attana 200-Dual Channel Referencing
CSO introduces Attana's new system for molecular interactions analysis
04:05 | September 4, 2009
In this video recorded at the IBC Drug Discovery & Development Week, CSO of Attana AB, Björn Ingemarsson, introduces the Attana 200 and, via a 3D animation cartoon, demonstrates biological interaction analysis using the example of monoclonal antibody characterization.
Attana AB is a pioneer in the development of continuous-flow QCM systems. Its new system, the Attana 200 is a dual channel, real time, label-free, continuous-flow system for characterization of molecular interactions. More... |
 |
EVOS fl Flourescence Microscope
AMG product demo at IBC Drug Discovery & Development Week
03:50 | September 1, 2009
Dr. Mark Rand, Product Manager of AMG (Advanced Microscopy Group), demonstrates the company's latest microscope, the EVOS fl for fluorescence imaging, at the IBC Drug Discovery and Development Week. The EVOS fl platform offers a fully integrated digital imaging system that includes an inverted microscope, high-resolution digital camera and an LCD display.
AMG, a division of Westover Scientific, Inc., focuses on designing, developing and offering innovative optical equipment for the life sciences market, including research and diagnostic laboratories. More... |
 |
The Automation Partnership (TAP) is an innovative UK company providing specialist automation systems and services to the global life science research industry.
In this video, Kim Bure, Associate Director - US Commercial Operations introduces TAP's CompacT and CompacT SelecT systems and partner products to a group of exhibit hall visitors participating in a product tour during the IBC Drug Discovery & Development Week. |
 |
Epitomics Inc.
The story of the Rabbit MonoClonal Antibody Company
09:54 | May 9, 2009
With proven success of the Rabbit MonoClonal Antibody technology in research and diagnostics, Epitomics is poised to brave the development of therapeutics. |
 |
In this segment, Charles Hsu discusses China's R&D capabilities, the rise of China's biotech industry, and its implications on the U.S. and China healthcare markets.
Mr. Hsu is a Venture Partner at Bay City Capital. He has over 25 years of experience in the life sciences industry, most of which as an entrepreneur and venture capitalist focusing on early-stage life science and health care firms. More...
|
 |
Tough Time Wisdom
A conversation with Charles Hsu, Ph.D., Bay City Capital - Part II
12:26 | February 20, 2009
In this segment, Charles Hsu expresses his views on the global financial crisis - its short term vs. long term impact, absolute vs. relative opportunities for investments, and potential positive effects of a down market.
Mr. Hsu is a Venture Partner at Bay City Capital. He has over 25 years of experience in the life sciences industry, most of which as an entrepreneur and venture capitalist focusing on early-stage life science and health care firms. More... |
 |
The System Is Not Optimal!
A conversation with Charles Hsu, Ph.D., Bay City Capital - Part III
09:33 | February 19, 2009
In this segment, Charles Hsu reflects on the U.S. drug development and commercialization system as a whole, from an investor's point of view.
Mr. Hsu is a Venture Partner at Bay City Capital. He has over 25 years of experience in the life sciences industry, most of which as an entrepreneur and venture capitalist focusing on early-stage life science and health care firms. More... |
 |
The State of China Biotech - Part I
Facts and Figures from ChinaBio - Driving Factors and Government Programs
10:43 | February 18, 2009
Greg Scott, President of ChinaBio, presents research data for 2008 for the first time, at an executive workshop held at Wilson Sonsini Goodrich & Rosati in San Francisco during the JP Morgan 27th Annual Healthcare Conference.
In this segment, Mr. Scott highlights 10 driving factors behind China's biopharmaceutical industry, and specifically the major government programs as one of the key factors. |
 |
The State of China Biotech - Part II
Facts and Figures from ChinaBio - Technology Development and Clinical Trial Activity
08:02 | February 17, 2009
Greg Scott, President of ChinaBio, presents research data for 2008 for the first time, at an executive workshop held at Wilson Sonsini Goodrich & Rosati in San Francisco during the JP Morgan 27th Annual Healthcare Conference.
This segment focuses on technology development as manifested by patent trends - analyzed by indication, sources and location; and on clinical trial activity and current status.
|
 |
The State of China Biotech - Part III
Facts and Figures from ChinaBio - VC Investments, M&A and IPO Activities
12:47 | February 16, 2009
Greg Scott, President of ChinaBio, presents research data for 2008 for the first time, at an executive workshop held at Wilson Sonsini Goodrich & Rosati in San Francisco during the JP Morgan 27th Annual Healthcare Conference.
In this segment, Mr. Scott summarizes research findings on partnering, M&A, IPO and VC investment activities. |
| © 2008-2009 Song Essinova, LLC |
About Essinova | Essinova Services | Privacy Policy | Terms of Use | Contact Essinova |
